Posts

Teva's Innovation Engine Offsets Generics Slump, Leaving Analyst Shocked by Ajovy Surge

on
Teva's innovation engine mitigates generics slump Ajovy faces unexpected surge Analyst shocked by Ajovy performance Teva's specialty portfolio outperforms expectations Generics revenue declines despite pricing pressure Teva's growth driven by innovative brands and emerging markets Teva's innovation pipeline shows promising results Ajovy positions Teva as a leader in migraine treatments Teva maintains focus on innovation despite generics challenges Teva's strategic shift toward specialty drugs and innovation Teva's innovation strategy offsets generics slowdown Teva's strong performance in key therapeutic areas Ajovy's surge challenges analyst expectations Teva's innovation-driven growth model gains traction Teva's specialty brands drive overall revenue growth Analysts reassess Teva's valuation based on innovation success Teva's innovation engine inspires confidence in long-term growth T...

AbbVie Scores First Rinvoq Alopecia Nod in EU

on

Biogen flips 2026 revenue guidance from expected decline to sales increase

on

Atea's hep C pill equal to Gilead's

on

Claris collects $118M to take eye drop into pivotal testing next year

on

Altimmune’s Next-Gen GLP-1 Curbs Heavy Drinking in Unequivocal Phase 2 alcohol use disorder win

on

MannKind Receives FDA Approval for Furoscix ReadyFlow Autoinjector for Edema in Heart Failure and CKD

on

GSK unveils 3‑year cost‑saving plan to fund late‑stage R&D and move research HQ to Cambridge from AZ”,

on

FDA's re‑evaluation of Capricor and Replimune drugs underscores that review ≠ reversal

on

RA Capital Launches Rare Disease Company Oak Hill Bio onto Nasdaq via SPAC

on

FDA Staff Signal Replimune RP1 Melanoma Trial Failure, Slashing Stock

on

Apnimed Targets Up to $160M IPO for Sleep Apnea Drug Oxnimbi Launch

on

Assured Raises $19 Million Series A to Accelerate AI-Driven Provider Credentialing

on